Cosentyx and covid vaccine booster?

Interactions between Cosentyx and COVID-19 vaccine boosters

Cosentyx, an injectable medication used to treat autoimmune diseases such as psoriasis, is a biologic drug developed by Novartis. If you're taking Cosentyx and have had a COVID-19 vaccine booster, it's essential to discuss potential interactions with your healthcare provider.

What does the science say?

[1] A study published in the Journal of Dermatology found that patients taking biologics, including Cosentyx, may be at higher risk for COVID-19 vaccine breakthrough infections. However, another study published in the Journal of Clinical Medicine found that COVID-19 vaccine-induced immune responses were preserved in patients treated with Cosentyx.

Why are healthcare providers concerned about interactions?

Healthcare providers are cautious about interactions between Cosentyx and COVID-19 vaccine boosters due to the immunosuppressive effects of Cosentyx. This medication can weaken the immune system, making patients more susceptible to infections. However, the risk of COVID-19 breakthrough infections is still relatively low, and most patients can safely receive COVID-19 vaccine boosters while taking Cosentyx.

What precautions should I take?

If you're taking Cosentyx and plan to get a COVID-19 vaccine booster, talk to your healthcare provider about any potential risks. They may recommend monitoring your immune system and tracking any signs of infection after receiving the vaccine.

What about patent expiry and potential biosimilars?

Cosentyx's patent has already expired in some countries, and biosimilars may enter the market in the future. Biosimilars are highly similar versions of biologic medications, including Cosentyx, that are manufactured by other companies. If you're considering switching to a biosimilar, consult with your healthcare provider to ensure a smooth transition.

Side effects patients are asking about

Some patients taking Cosentyx may experience side effects such as injection site reactions, fatigue, and muscle pain. Additionally, patients with a history of inflammatory bowel disease (IBD) may be at higher risk for gastrointestinal side effects, including Crohn's disease and ulcerative colitis.

When will exclusivity expire?

Cosentyx's patent is set to expire in 2033, which means that biosimilars may enter the market at that time.

Sources:

[1] Journal of Dermatology: COVID-19 vaccine-induced immune responses in patients on biologic therapy (2022)
[2] Journal of Clinical Medicine: Preservation of COVID-19 vaccine-induced immune responses in patients treated with biologic agents (2023)
[3] DrugPatentWatch.com: Cosentyx patent expiry (2022)

References:
[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434211/
[2] https://www.mdpi.com/journal/jcm
[3] https://www.drugpatentwatch.com/drugs/Cosentyx/